Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnrichPSMA
NCT07025369Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2025
- Primary completion
- Jan 2029
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (3 arms), sponsored by Mayo Clinic. Primary endpoints: Maximum standard uptake value at Day 15 and Mean standard uptake value at Day 15. Started Aug 2025; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07025369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025369.